Projects
Xenotransplantation of genetically engineered iPSC-derived microglia and neurons to decipher the cell-type specific interplay of Progranulin and TMEM106B in neuroinflammation and neurodegeneration. University of Antwerp
MACSiMiSE-BRAIN: Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration Hasselt University
MACSiMiSE-BRAIN: Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration University of Antwerp
Elucidating mechanisms underlying aggregation/spreading of RNA binding proteins in neurodegeneration KU Leuven
Aggregation of disease-causing proteins harboring a low complexity/prion-like domain is a common hallmark of most neurodegenerative disorders. In particular aberrant cytoplasmic accumulation of the misfolded RNA binding proteins, FUS (Fused in Sarcoma) and TDP-43 (Transactive response DNA-binding protein 43) is a nearly universal feature of most Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) cases, the second most ...
Chronic inflammation and blood brain barrier disruption in neurodegeneration Hasselt University
Exploring a new arm of the integrated stress response and its connection to neurodegeneration Flanders Institute for Biotechnology
Mapping amyloid-induced neurodegeneration in the gut using MALDI imaging. University of Antwerp
Investigating the role of tau aggregates in neurodegeneration KU Leuven
The PhD project investigates the role of tau aggregates in neurodegeneration and is part of a wider project that focusses on the discovery of novel monoclonal antibodies that can neutralize tau toxicity and spreading. Tau is the main component of the neurofibrillary tangles that are a hallmark of AD along with Alzheimer beta plaques, and a paradigm of intracellular aggregation. In the etiology of AD, the Abeta aggregation and the abnormal ...
The role of the peripheral immune system on neurodegeneration and neuroinflammation in rodent models for Parkinson’s disease KU Leuven
Parkinson’s disease (PD) is the most common neurodegenerative motor disorder. No therapy can cure, stop or slow down the progression of the disease, as only symptomatic treatment strategies are available. Identifying pathogenic mechanisms underlying neurodegeneration will therefore be essential to develop a disease-modifying drug. PD is characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) and the ...